Cargando…

(−)-Oleocanthal Combined with Lapatinib Treatment Synergized against HER-2 Positive Breast Cancer In Vitro and In Vivo

Dysregulation of epidermal growth factor receptor (EGFR)/human epidermal growth factor-2 (HER2) family is a hallmark of aggressive breast cancer. Small-molecule tyrosine kinase inhibitors are among the most effective cancer targeted treatments. (−)-Oleocanthal (OC) is a naturally occurring phenolic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Siddique, Abu Bakar, Ebrahim, Hassan Y., Akl, Mohamed R., Ayoub, Nehad M., Goda, Amira A., Mohyeldin, Mohamed M., Nagumalli, Suresh K., Hananeh, Wael M., Liu, Yong-Yu, Meyer, Sharon A., El Sayed, Khalid A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6412724/ https://www.ncbi.nlm.nih.gov/pubmed/30781364 http://dx.doi.org/10.3390/nu11020412

Ejemplares similares

Olive Phenolics as c-Met Inhibitors: (-)-Oleocanthal Attenuates Cell Proliferation, Invasiveness, and Tumor Growth in Breast Cancer Models
por: Akl, Mohamed R., et al.
Publicado: (2014)

The Maxi-K (BK) Channel Antagonist Penitrem A as a Novel Breast Cancer-Targeted Therapeutic
por: Goda, Amira A., et al.
Publicado: (2018)

The oleocanthal-based homovanillyl sinapate as a novel c-Met inhibitor
por: Mohyeldin, Mohamed M., et al.
Publicado: (2016)

Araguspongine C Induces Autophagic Death in Breast Cancer Cells through Suppression of c-Met and HER2 Receptor Tyrosine Kinase Signaling
por: Akl, Mohamed R., et al.
Publicado: (2015)

(−)-Oleocanthal Prevents Breast Cancer Locoregional Recurrence After Primary Tumor Surgical Excision and Neoadjuvant Targeted Therapy in Orthotopic Nude Mouse Models
por: Siddique, Abu Bakar, et al.
Publicado: (2019)

Novel liquid-liquid extraction and self-emulsion methods for simplified isolation of extra-virgin olive oil phenolics with emphasis on (-)-oleocanthal and its oral anti-breast cancer activity
por: Siddique, Abu Bakar, et al.
Publicado: (2019)

Oleocanthal Attenuates Metastatic Castration-Resistant Prostate Cancer Progression and Recurrence by Targeting SMYD2
por: Siddique, Abu Bakar, et al.
Publicado: (2022)

Safety Evaluations of Single Dose of the Olive Secoiridoid S-(−)-Oleocanthal in Swiss Albino Mice
por: Siddique, Abu Bakar, et al.
Publicado: (2020)

Optimization of Taste-Masked (–)-Oleocanthal Effervescent Formulation with Potent Breast Cancer Progression and Recurrence Suppressive Activities
por: Tajmim, Afsana, et al.
Publicado: (2019)

Oleocanthal Enhances Amyloid-β Clearance from the Brains of TgSwDI Mice and in Vitro across a Human Blood-Brain Barrier Model
por: Qosa, Hisham, et al.
Publicado: (2015)

Comparative Gene Signature of (−)-Oleocanthal Formulation Treatments in Heterogeneous Triple Negative Breast Tumor Models: Oncological Therapeutic Target Insights
por: Qusa, Mohammed H., et al.
Publicado: (2021)

(−)-Oleocanthal as a Dual c-MET-COX2 Inhibitor for the Control of Lung Cancer
por: Siddique, Abu Bakar, et al.
Publicado: (2020)

(-)-Oleocanthal and (-)-oleocanthal-rich olive oils induce lysosomal membrane permeabilization in cancer cells
por: Goren, Limor, et al.
Publicado: (2019)

S-(−)-Oleocanthal Ex Vivo Modulatory Effects on Gut Microbiota
por: Qusa, Mohammed H., et al.
Publicado: (2023)

(-)-Oleocanthal Nutraceuticals for Alzheimer’s Disease Amyloid Pathology: Novel Oral Formulations, Therapeutic, and Molecular Insights in 5xFAD Transgenic Mice Model
por: Tajmim, Afsana, et al.
Publicado: (2021)

Comparison of Oleocanthal-Low EVOO and Oleocanthal against Amyloid-β and Related Pathology in a Mouse Model of Alzheimer’s Disease
por: Abdallah, Ihab M., et al.
Publicado: (2023)

Absorption and Intestinal Metabolic Profile of Oleocanthal in Rats
por: López-Yerena, Anallely, et al.
Publicado: (2020)

Oleacein and Oleocanthal: Key Metabolites in the Stability of Extra Virgin Olive Oil
por: Olmo-Cunillera, Alexandra, et al.
Publicado: (2023)

Lapatinib Plasma and Tumor Concentrations and Effects on HER Receptor Phosphorylation in Tumor
por: Spector, Neil L., et al.
Publicado: (2015)

Combining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancer
por: Leung, Wing-yin, et al.
Publicado: (2015)

A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer
por: Cristofanilli, Massimo, et al.
Publicado: (2012)

Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases – the UK experience
por: Sutherland, S, et al.
Publicado: (2010)

Structural investigations on mechanism of lapatinib resistance caused by HER-2 mutants
por: Verma, Sharad, et al.
Publicado: (2018)

The Biological Activities of Oleocanthal from a Molecular Perspective
por: Pang, Kok-Lun, et al.
Publicado: (2018)

(−)-Methyl-Oleocanthal, a New Oleocanthal Metabolite Reduces LPS-Induced Inflammatory and Oxidative Response: Molecular Signaling Pathways and Histones Epigenetic Modulation
por: Montoya, Tatiana, et al.
Publicado: (2021)

Synergistic Activity of the HSP90 Inhibitor Ganetespib With Lapatinib Reverses Acquired Lapatinib Resistance in HER2-Positive Breast Cancer Cells
por: Ye, Min, et al.
Publicado: (2021)

Dacomitinib, but not lapatinib, suppressed progression in castration-resistant prostate cancer models by preventing HER2 increase
por: Jathal, Maitreyee K., et al.
Publicado: (2019)

Crizotinib, a MET inhibitor, inhibits growth, migration, and invasion of breast cancer cells in vitro and synergizes with chemotherapeutic agents
por: Ayoub, Nehad M, et al.
Publicado: (2017)

Molecular effects of lapatinib in patients with HER2 positive ductal carcinoma in situ
por: Estévez, Laura G, et al.
Publicado: (2014)

Molecular effects of Lapatinib in the treatment of HER2 overexpressing oesophago-gastric adenocarcinoma
por: De Silva, Nadeera, et al.
Publicado: (2015)

Metastatic, Her-2 Amplified Lacrimal Gland Carcinoma with Response to Lapatinib Treatment
por: Dennie, Trevor
Publicado: (2015)

Th1 cytokines sensitize HER-expressing breast cancer cells to lapatinib
por: Showalter, Loral E., et al.
Publicado: (2019)

Tissue Distribution of Oleocanthal and Its Metabolites after Oral Ingestion in Rats
por: López-Yerena, Anallely, et al.
Publicado: (2021)

Current Disease-Targets for Oleocanthal as Promising Natural Therapeutic Agent
por: Segura-Carretero, Antonio, et al.
Publicado: (2018)

Exploring the Immunotherapeutic Potential of Oleocanthal against Murine Cutaneous Leishmaniasis
por: Karampetsou, Kalliopi, et al.
Publicado: (2022)

Effects of Lapatinib on HER2-Positive and HER2-Negative Canine Mammary Carcinoma Cells Cultured In Vitro
por: Leis-Filho, Antonio Fernando, et al.
Publicado: (2021)

Lapatinib and lapatinib plus trastuzumab therapy versus trastuzumab therapy for HER2 positive breast cancer patients: an updated systematic review and meta-analysis
por: Yuan, Ye, et al.
Publicado: (2022)

Combination effect of lapatinib with foretinib in HER2 and MET co-activated experimental esophageal adenocarcinoma
por: Hassan, Md. Sazzad, et al.
Publicado: (2019)

Different mechanisms for resistance to trastuzumab versus lapatinib in HER2- positive breast cancers -- role of estrogen receptor and HER2 reactivation
por: Wang, Yen-Chao, et al.
Publicado: (2011)

Lapatinib access into normal brain and brain metastases in patients with Her-2 overexpressing breast cancer
por: Saleem, Azeem, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_p2s2nbo86118b3h6kvc01df4qc